BLLN · XBRL financial data

BillionToOne financial statements, every quarter

The same tables from 4 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BLLN's year ends in late December)

In thousands of dollars	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	83,523	96,053*	108,388	109,448
Cost of goods and services sold	25,107	27,449*	29,292	32,341
Gross profit	58,416	68,604*	79,096	77,107
Research and development	12,953	14,250*	14,692	17,315
Selling, general and administrative	35,830	44,022*	46,570	54,289
Total operating expenses	48,783	58,272*	61,262	71,604
Operating income (loss)	9,633	10,332*	17,834	5,503
Interest income	1,535	3,258*	4,645	4,694
Interest expense	20	3*	10	8
Other income (expense)	(1,630)	(5,819)*	301	297
Income tax expense (benefit)	(129)	320*	539	(536)
Net income (loss)	5,711	5,977*	17,970	8,054
Earnings per share, basic USD per share	0.14	—	0.39	0.17
Earnings per share, diluted USD per share	0.10	—	0.34	0.15
Weighted average shares, basic thousands of shares	10,430	—	45,933	46,403
Weighted average shares, diluted thousands of shares	15,572	—	53,028	54,456

Fiscal quarters (BLLN's year ends in late December)

In thousands of dollars	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	195,152	495,975	537,450	548,628
Accounts receivable	34,646	41,617	61,305	74,894
Inventory	17,389	17,545	19,217	21,135
Prepaid and other current assets	4,529	5,421	6,166	6,719
Total current assets	251,716	560,558	624,138	651,376
Property and equipment, net	18,667	20,361	22,277	24,932
Right-of-use asset	48,024	46,742	49,396	47,829
Total assets	327,521	632,654	700,727	729,696
Accounts payable	7,806	7,184	8,702	12,205
Current portion of long-term debt	—	0	—	—
Total current liabilities	40,785	47,962	57,162	55,725
Long-term debt	—	57,226	—	—
Lease liability, non-current	47,046	45,723	47,695	45,981
Total liabilities	147,625	152,549	195,107	192,890
Accumulated deficit	(280,724)	(274,747)	(256,777)	(248,723)
Total stockholders' equity	(239,513)	480,105	505,620	536,806
Total liabilities and equity	327,521	632,654	700,727	729,696
Common shares outstanding (cover page) thousands of shares	11,178	—	—	—

Fiscal quarters (BLLN's year ends in late December)

In thousands of dollars	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	5,711	5,977*	17,970	8,054
Stock-based compensation	4,475*	6,334*	6,510	8,216*
Depreciation and amortization	—	year only	—	—
Net cash from operating activities	9,996*	10,792*	15,430	9,136*
Purchases of property and equipment	2,123*	1,537*	4,471	4,049*
Net cash from investing activities	(2,123)*	(1,578)*	(4,471)	(4,049)*
Share repurchases	—	0*	—	—
Net cash from financing activities	(1,679)*	291,609*	30,516	6,091*
Net change in cash	6,194*	300,823*	41,475	11,178*

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
BillionToOne	548,628	109,448	9,136*	not reported	—	Q2 FY26 10-QJun 30, 2026
Castle Biosciences	62,116	103,546	15,201*	30.5M	—	Q2 FY26 10-QJun 30, 2026
CareDx	250,480	139,362	12,718*	52.5M	—	Q3 FY26 10-QSep 30, 2026
Fulgent Genetics	26,305	85,389	(23,758)*	27.5M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Veracyte	299,521	150,321	45,826*	80.4M	—	Q2 FY26 10-QJun 30, 2026
CapForce	144	50,000	(618)*	12.4M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Caris Life Sciences	not reported	263,712	28,477*	282.6M	—	Q2 FY26 10-QJun 30, 2026
Lumexa Imaging Holdings	69,705	264,162	32,801*	96.1M	—	Q2 FY26 10-QJun 30, 2026
GRAIL	55,645	44,687	(80,730)*	44.7M	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.